An Open Label Study to Evaluate the Safety and Efficacy of BOR15001L7 for the Treatment of Cold Sores in Patients With Recurrent Herpes Labialis

Inclusion Criteria: * Provide signed informed consent and willing to comply with study-related procedures; * Males and females ≥18 years of age at screening; * Diagnosed with recurrent herpes labialis, defined as showing at least 2 episodes of infections per year; * Willing to avoid, during the treatment phase, the use of anti-inflammatory, anti-herpetic, antibiotic and antiviral agents as well as steroids or other natural products that would interfere with the immune system response (exception: only the use of valacyclovir will be permitted, if prescribed); * Willing to avoid, during the treatment phase, the use of cosmetic products (ex. cream, make-up, etc.) at areas close to the infected region. Exclusion Criteria: * Patients with skin disease affecting the peribuccal region (eczema, psoriasis, dermatitis, etc.); * Patients with herpes labialis occurring within 14 days prior to screening; * Patients known for allergies or intolerance to drug and comparator ingredients, or any cream used to treat skin conditions; * Treatment with an investigational product or biological agent or device within 30 days or five half˗lives, whichever is longer. * Any other condition, which, in the opinion of the investigator or the sponsor would make the patient unsuitable for inclusion, or could interfere with the conduct of the study.